Search

Displaying results 1321 - 1330 of 5383 in total
  1. Drug

    Cryptenamine

    go.drugbank.com/drugs/DB00785
    Approved

    It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects.

  2. Drug

    Amylocaine

    go.drugbank.com/drugs/DB09088
    ApprovedWithdrawn

    , and prilocaine in the 1940s and 1950s superseded and made the use of amylocaine obsolete. … Even though it certainly possessed less severe side effects than cocaine [L1882], the eventual development and clinical use of newer, more effective, and even safer local anesthetics like lidocaine, bupivicaine

  3. Drug

    Brilliant blue G

    go.drugbank.com/drugs/DB15594
    Approved

    It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830]

  4. Drug

    Etamivan

    go.drugbank.com/drugs/DB08989
    ApprovedWithdrawn

    Etamivan (INN) or ethamivan (USAN) is marketed under the name Analepticon. Etamvin is a respiratory stimulant drug similar to nikethamide. It is no longer used in the United States.

  5. Drug

    Topsalysin

    go.drugbank.com/drugs/DB05160
    Investigational

    Topsalysin is being developed for the treatment of localized prostate cancer and also benign prostatic hyperplasia. Topsalysin is delivered locally to the prostate under ultrasound guidance.

  6. Drug

    Leptin

    go.drugbank.com/drugs/DB05098
    Investigational

    Thus, obesity develops when people take in more energy than they use over a prolonged period of time, and this excess food intake is not driven by hunger signals, occurring in spite of the anti-appetite

  7. Drug

    Betahistine

    go.drugbank.com/drugs/DB06698
    ApprovedInvestigational

    [A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy. … It is currently marketed in Canada by various companies, including Teva Pharmaceuticals.

  8. Drug

    Cipaglucosidase alfa

    go.drugbank.com/drugs/DB16708
    ApprovedInvestigational

    [A232955, A232960] In December 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended cipaglucosidase alfa be granted marketing authorization for the treatment of Pompe disease … Cipaglucosidase alfa (ATB200) is a novel recombinant human acid alpha-glucosidase (GAA) investigated for the treatment of patients with Pompe disease, a rare inherited metabolic disorder characterized by

  9. Drug

    Tabelecleucel

    go.drugbank.com/drugs/DB17072
    ApprovedInvestigational

    [A253292,A253297,L43557] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended tabelecleucel be granted marketing authorization for the treatment of adult and … It is produced by mixing T-cells with B-cells that have been infected with the Epstein-Barr virus (EBV).

  10. Drug

    Asparaginase Escherichia coli

    go.drugbank.com/drugs/DB00023
    ApprovedInvestigational

    For patients who develop hypersensitivity to _E. coli_-derived formulations of L-asparaginase, the use of PEGylated or non-PEGylated [DB08886] is recommended [A31999]. … Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia